Stiolto™ Respimat®

March 31, 2016May 13, 2016

Stiolto Respimat for COPD Granted FDA’s Supplemental NDA Approval

Chronic Bronchitis, COPD, Emphysema, News

The FDA has approved a supplemental New Drug Application (sNDA) for Boehringer Ingelheim’s Stiolto Respimat, which, according to the company, adds data to the product’s label demonstrating improvements in health and quality ... Read more

February 10, 2016February 10, 2016

Lung Function in COPD Patients Shows Promise With STIOLTO RESPIMAT Inhalation Spray

COPD, News

Boehringer Ingelheim Pharmaceuticals announced the publication of promising new data regarding its inhalation spray, STIOLTO RESPIMAT, in the improvement of lung function when compared to therapy with an European formulation combining ... Read more

July 1, 2015November 9, 2015

COPD Treatment STIOLTO RESPIMAT Now Available Nationwide

COPD, News

Following the US Food and Drug Administration‘s final approval of Boehringer Ingelheim Pharmaceuticals, Inc.‘s STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray in May 2015, the company recently announced that patients with ... Read more

May 29, 2015November 9, 2015

FDA Approves Boehringer Ingelheim’s Stiolto Respimat as Maintenance Treatment for Patients With COPD

COPD, News

Boehringer Ingelheim announced that the FDA has approved once-daily Stiolto™ Respimat® (tiotropium bromide and olodaterol) Inhalation Spray. The drug was approved for long-term continuation therapy of the obstruction of the airflow in chronic ... Read more